Dana-Farber Brigham Cancer Center
Dana-Farber Brigham Cancer Center is a major oncology Center of Excellence combining the cancer expertise of Dana-Farber Cancer Institute with the clinical and hospital infrastructure of Mass General Brigham. The platform provides specialized cancer care across medical oncology, surgical oncology, radiation oncology, hematologic malignancies, immunotherapy, precision medicine, and clinical trials.
- Highest 2026 tier: Tier II
- Centers of Excellence
- 1 ranking category
Overview
Dana-Farber Brigham Cancer Center is a major oncology Center of Excellence combining the cancer expertise of Dana-Farber Cancer Institute with the clinical and hospital infrastructure of Mass General Brigham. The platform provides specialized cancer care across medical oncology, surgical oncology, radiation oncology, hematologic malignancies, immunotherapy, precision medicine, and clinical trials.
Its strength lies in the integration of academic research and advanced clinical care. Cancer care increasingly depends on molecular diagnostics, targeted therapies, cell therapy, multidisciplinary tumor boards, and access to investigational treatments. Dana-Farber Brigham’s model is structured around these complex oncology needs.
Dana-Farber Brigham Cancer Center is included in 1 2026 ranking category. Its highest classification is Tier II. Ranking recognition is category-specific editorial evidence rather than a substitute for independent diligence.
Firm facts
| Public identity | Dana-Farber Brigham Cancer Center |
| Founded | 1947 |
| Institution type | Centers of Excellence institution |
| Headquarters | Boston, United States |
| Primary focus | Centers of Excellence |
| Highest 2026 ranking tier | Tier II |
Principal activities
Its strength lies in the integration of academic research and advanced clinical care. Cancer care increasingly depends on molecular diagnostics, targeted therapies, cell therapy, multidisciplinary tumor boards, and access to investigational treatments. Dana-Farber Brigham’s model is structured around these complex oncology needs.
Core capability
Centers of Excellence
Client relevance
Category-specific capability, institutional credibility and the ability to support demanding professional, commercial or patient needs.
Execution and verification
Current service scope, leadership, geographic coverage, legal entities and regulated activities should be confirmed directly.
Sector and mandate coverage
Primary category
Centers of Excellence
Institutional context
Coverage reflects the institution’s role in the ranking categories listed below. Precise services, products, jurisdictions, clinical scope and client eligibility should be verified for each use case.
Market position
Dana-Farber Brigham’s focused oncology identity, research depth, academic affiliations, and specialist clinical platform support its inclusion among established Centers of Excellence.
Dana-Farber Brigham Cancer Center is assessed through public institutional information and Ranking News editorial research. Its strongest 2026 result is Tier II.
Competitive context
The relevant peer set varies by category, geography, client segment and mandate. Dana-Farber Brigham Cancer Center should be compared on current category-specific capability, senior involvement, evidence of comparable work, operating resilience and any applicable regulatory or clinical permissions.
Comparable institutions are shown for navigation and market context. Inclusion does not imply identical scale, ownership, geographic coverage, service model or regulatory status.
Leadership and governance
Leadership, ownership, governance and senior-team responsibilities may change. Current information should be verified through authoritative institutional sources.
Corporate and public information
The public-facing organization is identified here as Dana-Farber Brigham Cancer Center. Contracting entities, regulated affiliates, clinical operations, offices and legal permissions may differ by service and jurisdiction.
Corporate and disclosure information
| Organization | Dana-Farber Brigham Cancer Center |
| Headquarters | Boston, United States |
| Verification note | Confirm legal entity, licenses, offices and engagement terms directly before appointment or use. |
Rankings and recognition
Ranking inclusion and tier classification are editorial determinations. They should be read as category-specific assessments rather than universal league-table positions. The existence or maintenance of this Wiki profile does not influence ranking eligibility, tier or position.
Related Economy analysis
Selected reporting and market analysis from The Economy provides context for the institution’s operating environment:
- Healthcare Rankings and the New Economics of Expertise
- Healthcare Market Structure Is Opening a New Lane for Specialist Providers
- Healthcare Rankings and the New Geography of Distributed Care
Related institutions and subjects
Sources and data transparency
Official institutional information, where available, is used for current public identity and capabilities. Ranking pages document 2026 category and tier status. Economy articles provide market context rather than institution-specific endorsement.
- Healthcare Ranking — Top 30 Centers of Excellence 2026 — 2026 inclusion and tier classification.
- The Economy — Healthcare Rankings and the New Economics of Expertise — market context.
- The Economy — Healthcare Market Structure Is Opening a New Lane for Specialist Providers — market context.
- The Economy — Healthcare Rankings and the New Geography of Distributed Care — market context.
